Almirall partner MC2 on the verge of EU victory after ten years of hard work

The fact that MC2 therapeutics is close to its EU and US launch for the psoriasis treatment Wynzora is a significant milestone, says CEO Jesper Lange.

Photo: MC2 Therapeutics / PR

On Tuesday, MC2 Therapeutics and its partner Almirall announced that they had completed the EU decentralized procedure for the psoriasis treatment Wynzora, which is the last step before individual the health authorities in individual European countries can start issuing marketing authorizations.

For MC2, which developed Wynzora, the fact that the drug is on the brink of being launched in the EU and the US is the culmination of many years of work. It was approved in the US last year.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs